Operationalize: Expanded Access Programs
February 22 - 24, 2021 Completed
Nobody has claimed this event yet.
Organizers who claim their event pages can update listing details, add photos, answer to reviews, view click reports and more.Claim your free event listing
Overcome the Operational Hurdles Preventing You From Bringing Treatments to Patients in Need
Operationalize: Expanded Access Programs is the response to the industry’s plea for a greater understanding and clarity regarding the end-to-end management of running a treatment led EAP. With every speaker sharing the same desire to increase the success, ease and treatment options for patients in need, ensure that you are part of this voice.
This is your only opportunity to learn from large pharma, leading biotech’s, academic researchers and patient advocates all in the same room, allowing in-depth discussions on key topics such as:
- Organizing the logistical supply and demand of products across multiple borders depending on product needs and country specific guidelines
- Considering the ways in which technological advances can enable enhanced data procurement, patient communication and project streamlining to optimize program management
- Taking away key lessons when comparing the EU and US landscape for EAP regulatory navigation.
- Reconnecting with the patient to ensure the EAP remains transparent, fair and treatment oriented
As the demand for compassionate/ managed access programs becomes an ever- expected avenue for drug acquisition, join us to further your understanding of how to set up, operationalize, communicate, deliver and close out your altruistic program without running into ethical, financial or distributional challenges.
Speakers: Paul Aliu, Novartis, Christine MacCracken, Janssen, Erika Segear, Duke University, Georges van Baelen, Arctiryon, Lisa Kearns, NYU Grossman School of Medicine, Dawn Sullivan, Ultragenyx Pharmaceuticals, Jessa Ford Depew, Santhera Pharmaceuticals, Jodi Wolff, Santhera Pharmaceuticals, Donna Cowan, Stealth BioTherapeutics, Philipp Schlatter, Roche, Greg Tuyteleers, Janssen, Ramona Reichenbach, Novartis, Paula Singer, Alnylam Pharmaceuticals, Gretchen Randlett, Eli Lilly, Samantha Nunes-Radimerski, Novartis, Richard Klein, GE2P2 Global Foundation, Erin Lambert, Argenx, Lea Ann Browning-McNee, Reagan-Udall Foundation, Torunn Thingstad, Janssen
Time: on Monday February 22, 2021 at 9:00 am (ends Wednesday February 24, 2021 at 5:00 pm)
Reviews are public and modifiable.